A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients

European Psychiatry

Volumn 27, Issue 1, 2012, Pages 50-55

  Mackin, P ^a   Waton, T ^a   Watkinson, H M ^a   Gallagher, P ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antipsychotics; Cardiovascular risk; Diabetes; Lipid lowering therapy; Metabolic syndrome; Obesity

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; DITERPENES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84655164990     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.08.011     Document Type: Article

References (26)

1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
2. The electronic Medicines Compendium. Datapharm Communications Limited, 2010 []. http://www.medicines.org.uk/.
3. National Institute for Health and Clinical Excellence. Clinical Guideline 82. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care, 2010.
4. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
5. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
6. Bernardo M., Canas F., Banegas J.R., Casademont J., Riesgo Y., Varela C. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009, 24:431-441.
7. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010;119:101-9.
8. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006, 67:575-583.
9. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., Moller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
10. Duncan E.J., Woolson S.L., Hamer R.M., Dunlop B.W. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol 2009, 24:204-213.
11. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005, 80:45-53.
12. Henderson D.C., Copeland P.M., Borba C.P., Daley T.B., Nguyen D.D., Cagliero E., et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006, 67:789-797.
13. Henderson D.C., Nguyen D.D., Copeland P.M., Hayden D.L., Borba C.P., Louie P.M., et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005, 66:1116-1121.
14. Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1061-1071.
15. Levy J.C., Matthews D.R., Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-2192.
16. Mackin P., Bishop D., Watkinson H., Gallagher P., Ferrier I.N. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007, 191:23-29.
17. Mackin P., Bishop D.R., Watkinson H.M. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007, 7:28.
18. Morrato E.H., Druss B., Hartung D.M., Valuck R.J., Allen R., Campagna E., et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010, 67:17-24.
19. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68 (Suppl. 4):8-13.
20. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry 2007, 64:242-249.
21. Osborn D.P., Nazareth I., King M.B. Risk for coronary heart disease in people with severe mental illness: cross-sectional comparative study in primary care. Br J Psychiatry 2006, 188:271-277.
22. Parsons B., Allison D.B., Loebel A., Williams K., Giller E., Romano S., et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009, 110:103-110.
23. Smith R.C., Lindenmayer J.P., Davis J.M., Kelly E., Viviano T.F., Cornwell J., et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry 2009, 70:1501-1513.
24. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
25. Weinmann S., Read J., Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009, 113:1-11.
26. Yood M.U., DeLorenze G., Quesenberry C.P., Oliveria S.A., Tsai A.L., Willey V.J., et al. The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009, 18:791-799.